Drugs / Taclonex
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | TACLONEX | — | 2006-01-09 | fda.gov ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT03004339 Comparator | Aug 2016 → Feb 2017 | psoriasis | DFB Soria, LLC | Completed | No outcome recorded |
| Phase 4 | NCT00924950 Comparator | Jun → Dec 2009 | psoriasis | University of California, San Francisco | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Taclonex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00924950 ↗ |
| Route | Topical | “Taclonex Ointment/Hydrogel Patch Applied Topically Once Daily” NCT00924950 ↗ |